^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prostate Cancer
    Drug:cabazitaxel (Microtubule inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    03/17/2011
    Excerpt:
    Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Secondary therapy:
    prednisone; prednisolone
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Cabazitaxel Injection is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel- containing treatment regimen.
    Secondary therapy:
    prednisone
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Prostate cancer: Preferred regimens...Cabazitaxel/carboplatin
    Secondary therapy:
    carboplatin
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN Guidelines Panel included cabazitaxel as an option for secondline therapy after progression on docetaxel for patients with symptomatic metastatic CRPC.